Sumanta K Pal1, Sameer R Ghate2, Nanxin Li3, Elyse Swallow3, Miranda Peeples3, Miriam L Zichlin3, Jose Ricardo Perez4, Neeraj Agarwal5, Nicholas J Vogelzang6. 1. City of Hope Comprehensive Cancer Center, Duarte, CA. 2. Novartis Pharmaceuticals Corporation, East Hanover, NJ. Electronic address: sameer.ghate@novartis.com. 3. Analysis Group, Inc, Boston, MA. 4. Novartis Pharmaceuticals Corporation, East Hanover, NJ. 5. University of Utah Huntsman Cancer Institute, Salt Lake City, UT. 6. US Oncology Research, Comprehensive Centers of Nevada, Las Vegas, NV.
Abstract
BACKGROUND: The real-world survival outcomes and prognostic factors among patients receiving first-line targeted therapy for advanced renal cell carcinoma (aRCC) are not well known. PATIENTS AND METHODS: Adult patients diagnosed with RCC and treated with first-line targeted therapy were identified from the Surveillance, Epidemiology, and End Results-Medicare database (January 1, 1993 to December 31, 2012). The patients were grouped into early (2006-2009) or late (2010-2012) targeted therapy era cohorts by the year of the first-line targeted therapy initiation. Overall survival (OS) was measured from first-line targeted therapy initiation and compared between the 2 cohorts using Kaplan-Meier analyses. The prognostic factors for OS were assessed using a multivariable-adjusted Cox model. RESULTS: A total of 604 and 641 aRCC patients (mean age, 68 years; ∼60% male in both cohorts) initiated first-line targeted therapy during the early and late targeted therapy eras, respectively. OS was significantly longer in the late than in the early targeted therapy era. Higher tumor grades (hazard ratio [HR], 1.61; 95% confidence interval [CI], 1.31-2.00) and lung (HR, 1.27; 95% CI, 1.06-1.53), bone (HR, 1.37; 95% CI, 1.13-1.66), and liver (HR, 1.42; 95% CI, 1.10-1.84) metastases were associated with significantly shorter OS. Previous nephrectomy (HR, 0.55; 95% CI, 0.42-0.72) and pazopanib as first-line targeted therapy relative to sorafenib (HR, 0.56; 95% CI, 0.37-0.85) or sunitinib (HR, 0.65; 95% CI, 0.44-0.95) were associated with significantly longer OS. CONCLUSION: The results of these real-world analyses suggest progress in aRCC management and identified positive (nephrectomy, pazopanib vs. sunitinib or sorafenib) and negative (higher tumor grade and lung, bone, or liver metastasis) prognostic factors among patients receiving first-line targeted therapy.
BACKGROUND: The real-world survival outcomes and prognostic factors among patients receiving first-line targeted therapy for advanced renal cell carcinoma (aRCC) are not well known. PATIENTS AND METHODS: Adult patients diagnosed with RCC and treated with first-line targeted therapy were identified from the Surveillance, Epidemiology, and End Results-Medicare database (January 1, 1993 to December 31, 2012). The patients were grouped into early (2006-2009) or late (2010-2012) targeted therapy era cohorts by the year of the first-line targeted therapy initiation. Overall survival (OS) was measured from first-line targeted therapy initiation and compared between the 2 cohorts using Kaplan-Meier analyses. The prognostic factors for OS were assessed using a multivariable-adjusted Cox model. RESULTS: A total of 604 and 641 aRCC patients (mean age, 68 years; ∼60% male in both cohorts) initiated first-line targeted therapy during the early and late targeted therapy eras, respectively. OS was significantly longer in the late than in the early targeted therapy era. Higher tumor grades (hazard ratio [HR], 1.61; 95% confidence interval [CI], 1.31-2.00) and lung (HR, 1.27; 95% CI, 1.06-1.53), bone (HR, 1.37; 95% CI, 1.13-1.66), and liver (HR, 1.42; 95% CI, 1.10-1.84) metastases were associated with significantly shorter OS. Previous nephrectomy (HR, 0.55; 95% CI, 0.42-0.72) and pazopanib as first-line targeted therapy relative to sorafenib (HR, 0.56; 95% CI, 0.37-0.85) or sunitinib (HR, 0.65; 95% CI, 0.44-0.95) were associated with significantly longer OS. CONCLUSION: The results of these real-world analyses suggest progress in aRCC management and identified positive (nephrectomy, pazopanib vs. sunitinib or sorafenib) and negative (higher tumor grade and lung, bone, or liver metastasis) prognostic factors among patients receiving first-line targeted therapy.
Authors: Anas M Saad; Mohamed M Gad; Muneer J Al-Husseini; Inas A Ruhban; Mohamad Bassam Sonbol; Thai H Ho Journal: Clin Genitourin Cancer Date: 2018-10-11 Impact factor: 2.872
Authors: Michele Marchioni; Marco Bandini; Raisa S Pompe; Zhe Tian; Tristan Martel; Anil Kapoor; Luca Cindolo; Francesco Berardinelli; Alberto Briganti; Shahrokh F Shariat; Luigi Schips; Pierre I Karakiewicz Journal: Int Urol Nephrol Date: 2017-09-20 Impact factor: 2.370
Authors: S Nazha; S Tanguay; A Kapoor; M Jewett; C Kollmannsberger; L Wood; G Bjarnason; D Heng; D Soulières; N Reaume; N Basappa; E Lévesque; A Dragomir Journal: Curr Oncol Date: 2018-12-01 Impact factor: 3.677
Authors: Michela Roberto; Andrea Botticelli; Martina Panebianco; Anna Maria Aschelter; Alain Gelibter; Chiara Ciccarese; Mauro Minelli; Marianna Nuti; Daniele Santini; Andrea Laghi; Silverio Tomao; Paolo Marchetti Journal: Front Oncol Date: 2021-04-22 Impact factor: 6.244